AG
ACAD icon

Aperio Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Aperio Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$2.05M Buy
38,326
+6,100
+19% +$303K 0.01% 1224
2020
Q3 		$1.33M Sell
32,226
-857
-3% -$37K ﹤0.01% 1303
2020
Q2 		$1.6M Buy
33,083
+3,262
+11% +$157K 0.01% 1205
2020
Q1 		$1.26M Buy
29,821
+1,868
+7% +$77K 0.01% 1209
2019
Q4 		$1.2M Buy
27,953
+3,385
+14% +$147K ﹤0.01% 1343
2019
Q3 		$884K Buy
24,568
+3,184
+15% +$96.5K ﹤0.01% 1459
2019
Q2 		$572K Buy
21,384
+4,127
+24% +$105K ﹤0.01% 1708
2019
Q1 		$463K Buy
17,257
+1,339
+8% +$31.3K ﹤0.01% 1791
2018
Q4 		$257K Buy
15,918
+239
+2% +$4.64K ﹤0.01% 2018
2018
Q3 		$325K Sell
15,679
-907
-5% -$14.3K ﹤0.01% 1969
2018
Q2 		$253K Sell
16,586
-1,007
-6% -$18K ﹤0.01% 2072
2018
Q1 		$395K Sell
17,593
-633
-3% -$17.5K ﹤0.01% 1808
2017
Q4 		$549K Buy
18,226
+195
+1% +$6.24K ﹤0.01% 1658
2017
Q3 		$679K Buy
18,031
+279
+2% +$9.08K ﹤0.01% 1505
2017
Q2 		$495K Sell
17,752
-3,199
-15% -$95.3K ﹤0.01% 1667
2017
Q1 		$720K Buy
20,951
+263
+1% +$9.28K ﹤0.01% 1333
2016
Q4 		$597K Buy
20,688
+2,131
+11% +$56.4K ﹤0.01% 1413
2016
Q3 		$590K Buy
18,557
+760
+4% +$25.8K ﹤0.01% 1358
2016
Q2 		$578K Sell
17,797
-1,167
-6% -$39.1K ﹤0.01% 1314
2016
Q1 		$530K Buy
18,964
+4,335
+30% +$94.5K ﹤0.01% 1333
2015
Q4 		$522K Buy
14,629
+769
+6% +$27.1K ﹤0.01% 1319
2015
Q3 		$458K Sell
13,860
-296
-2% -$12.3K ﹤0.01% 1347
2015
Q2 		$593K Buy
14,156
+5,290
+60% +$205K 0.01% 1232
2015
Q1 		$289K Buy
8,866
+93
+1% +$3.2K ﹤0.01% 1596
2014
Q4 		$279K Buy
+8,773
New +$249K ﹤0.01% 1550
2014
Q2 		– Sell
-8,421
Closed -$205K – 1734
2014
Q1 		$205K Buy
+8,421
New +$213K ﹤0.01% 1851
2013
Q4 		– Sell
-7,986
Closed -$219K – 1983
2013
Q3 		$219K Buy
+7,986
New +$167K ﹤0.01% 1596

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Aperio Group's ACAD Position: Q4 2020 in Review

Aperio Group increased its Acadia Pharmaceuticals (ACAD) stake by 19% in Q4 2020, buying an estimated $303K and bringing the position to 38,326 shares worth $2.05M. The position accounts for 0.01% of the portfolio, ranked #1224.

Aperio Group first reported a position in ACAD in Q3 2013 and has held it in 27 quarters since. 308 funds tracked by Wall St. Rank hold ACAD as of Q4 2020.

  • Aperio Group held 38,326 shares of Acadia Pharmaceuticals worth $2.05M as of Q4 2020.
  • Aperio Group bought 6,100 Acadia Pharmaceuticals shares in Q4 2020, an estimated $303K.
  • Acadia Pharmaceuticals made up 0.01% of Aperio Group's portfolio in Q4 2020, its #1224 holding.
  • Aperio Group first reported a position in Acadia Pharmaceuticals in Q3 2013 and has held it in 27 quarters since.
  • 308 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.